The $2.1 Million Question: What Are The Medical, Ethical Implications Of The World's Priciest Drug? [Forbes]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Forbes
The $2.1 Million Question: What Are The Medical, Ethical Implications Of The World's Priciest Drug? Pau Barrena, AFP, Getty Images With last month ’ world’s most expensive medication rising price of medications watchdogs are outraged. They say Zolgensma is merely the latest example of unethical and monopolistic pricing strategies among drug manufacturers. In a Bloomberg No Miracle Drug Should Cost $2.1 Million “The drug industry will argue, as it always does, that unlimited and rapidly escalating prices are needed to recoup the costs of R&D,” Bach noted. However, Novartis neither researched nor developed Zolgensma. It simply acquired AveXis (the firm that did) for a price that Novartis will recoup in relative short order, according to analysts On the other side of the debate are the beneficiaries of Zolgensma, namely the parents of afflicted children. You cannot put a price on your child’s life In ethical controversies such as these, opposing sides rarely give ground. No one will con
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Global $20B+ Macular Degeneration Treatment Market Outlook, 2024-2029: AI Integration Paves the Way for Personalized Care [Yahoo! Finance]Yahoo! Finance
- Dyno Therapeutics Unveils Path to Exponentially Reducing the Cost of In Vivo Gene Delivery at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Dyno Therapeutics to Accelerate Design of High-Performance Biological Sequences Using NVIDIA AI [Yahoo! Finance]Yahoo! Finance
- Axmed raises $2M from Founderful to streamline drug supply chains in underserved markets [Yahoo! Finance]Yahoo! Finance
- Axmed raises $2M from Founderful to streamline drug supply chains in underserved markets [TechCrunch]TechCrunch
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- NVS's page on the SEC website